Back | Next |
home / stock / nbio / nbio message board
Subject | By | Source | When |
---|---|---|---|
I love the fundamentals here | Robertscott | investorshub | 07/11/2023 7:17:08 PM |
Time to rebound $NBIO | Robertscott | investorshub | 07/11/2023 7:16:30 PM |
$NBIO Nascent Biotech, Inc. ($NBIO) | jedijazz | investorshub | 07/11/2023 6:31:02 PM |
$NBIO has also been actively shoring up its | jedijazz | investorshub | 07/11/2023 5:46:03 PM |
You can see how thin $NBIO is on | jedijazz | investorshub | 07/11/2023 5:41:44 PM |
$NBIO 's lead candidate, Pritumumab (PTB), is a | jedijazz | investorshub | 07/11/2023 5:40:37 PM |
This could be a good signal to watch | Robertscott | investorshub | 07/11/2023 5:36:10 PM |
Check out $NBIO's website www.nascentbiotech.com. | Robertscott | investorshub | 07/11/2023 5:33:58 PM |
This could be a big one | Robertscott | investorshub | 07/11/2023 4:57:37 PM |
$NBIO recently presented its Phase I data at | jedijazz | investorshub | 07/11/2023 4:36:34 PM |
$NBIO Nascent Biotech Inc. is an emerging player | jedijazz | investorshub | 07/11/2023 4:21:08 PM |
Looks like only shares traded are people buying | Robertscott | investorshub | 07/11/2023 4:07:33 PM |
Ask time $NBIO | Robertscott | investorshub | 07/11/2023 4:06:55 PM |
$NBIO .05's are thin to a new HOD! | jedijazz | investorshub | 07/11/2023 4:01:28 PM |
Looking better...$NBIO is in the course of its | BlazingStocks | investorshub | 07/11/2023 3:30:31 PM |
$NBIO is in the course of its development | Robertscott | investorshub | 07/11/2023 3:26:21 PM |
$NBIO Nascent Biotech therapeutic antibody Pritumumab (PTB) is | jedijazz | investorshub | 07/11/2023 3:17:54 PM |
$NBIO very positive sentiment here! | jedijazz | investorshub | 07/11/2023 3:15:28 PM |
Thank you for sharing that article... Been watching | BlazingStocks | investorshub | 07/11/2023 2:50:14 PM |
Spread just tightened $NBIO | Robertscott | investorshub | 07/11/2023 2:38:35 PM |
News, Short Squeeze, Breakout and More Instantly...
NORTH PALM BEACH, FL / ACCESSWIRE / April 16, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, announces that it is embarking on a fresh manufacturin...
NORTH PALM BEACH, FL / ACCESSWIRE / March 19, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, and HypoSpray Pharma ("HypoSpray ® "), a clinical...
NORTH PALM BEACH, FL and NEW YORK, NY / ACCESSWIRE / February 6, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies for the treatment of various cancers and viral infections, announc...